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ABSTRACT
Vancomycin-resistant enterococci (VRE) have emerged as significant nosocomial pathogens. A hospital-
wide prevalence study was performed to identify cases with VRE faecal colonisation. A case-control
study using two randomly selected VRE-negative controls for each positive case was performed to
assess risk-factors for VRE colonisation by univariate and multivariate analysis. VRE faecal colonisation
was documented in 53 (14.3%) of 370 patients screened. Previous exposure to anti-anaerobic agents, as
well as quinolones, was associated with VRE colonisation (p <0.05). The presence of an invasive device
(OR 4.8, p 0.003) and the duration of any antimicrobial treatment before VRE isolation (OR 1.2, p <0.001)
predicted VRE colonisation in multivariate models. The crude mortality rate for patients with VRE
colonisation was 24.5%, but VRE colonisation was not an independent predictor of mortality in these
patients. These results suggest that an active surveillance programme focusing on specific patient
groups may help in the identification of VRE-colonised patients. Promptly implemented infection
control strategies targeting these groups should help to combat the rising incidence of VRE.
Keywords Colonisation, enterococci, mortality, risk-factors, vancomycin resistance, vancomycin-resistant entero-
cocci
Original Submission: 2 February 2007; Revised Submission: 22 June 2007; Accepted: 23 July 2007
Clin Microbiol Infect 2008; 14: 14–21
INTRODUCTION
Enterococci with acquired, plasmid-mediated,
high-level resistance to glycopeptide antimicro-
bial agents have been implicated increasingly in
nosocomial outbreaks that result in high morbid-
ity and mortality [1–4]. In 2003, 28.5% of entero-
coccal isolates from intensive care units (ICUs)
that were reported to the National Nosocomial
Infections Surveillance system in the USA were
resistant to vancomycin [5]. Strains of Enterococ-
cus faecium predominate among vancomycin-
resistant enterococci (VRE), with an average of
50% showing resistance to vancomycin [6,7].
Although Enterococcus faecalis is the most pre-
valent of all enterococci causing infections, more
recent data show an increase in the proportion
of infections caused by E. faecium, ranging from
15% to 20% [7]. An increasing prevalence of
vancomycin-resistant E. faecium isolates belong-
ing to the epidemic and virulent hospital-
adapted clonal complex-17 (CC-17) among
bloodstream isolates has been documented in
both North America and Europe as part of the
SENTRY antimicrobial surveillance programme
[8]. Reported VRE colonisation rates among
hospitalised patients vary widely, ranging from
1.5% to 32% [9–14], while the prevalence
of VRE among non-hospitalised patients is
1–3.5%, usually involving non-epidemic isolates
[11,14,15].
Newly detected VRE may represent either
acquisition of resistant organisms or genes (nos-
ocomial transmission) or expansion of pre-exist-
ing, but undetected, colonisation with VRE
following heavy exposure to antimicrobial agents
[16], rather than de-novo emergence of resistance
[17]. Thus, the likelihood of nosocomial VRE
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may vary according to the ‘colonisation pres-
sure’, i.e., the degree of endemicity of VRE in a
specific location, exposure to contaminated
equipment, and proximity to a VRE carrier, as
well as the ‘time at risk’, i.e., the duration of
hospitalisation [18]. However, it has been diffi-
cult to differentiate among the factors associated
with amplification of previously undetectable
colonisation and those associated with nosoco-
mial spread of VRE.
In February 2005, several isolates of VRE from
clinical specimens were noted in the University
General Hospital Attikon (Athens, Greece). These
specimens were derived from blood, urine, a
central venous catheter and a surgical wound
swab. Immediate therapeutic and infection con-
trol measures were implemented for the identi-
fied cases. In order to achieve a thorough
understanding of the epidemiology of VRE in
the hospital, a hospital-wide prevalence study
was conducted to identify patients who were
colonised with VRE. A case-control comparison
with non-colonised patients was then performed
to evaluate the risk-factors for colonisation.
MATERIALS AND METHODS
Study site and ethical approval
The study was undertaken between 20 April and 30 May 2005
in Attikon General Hospital, a 330-bed tertiary university
hospital in Athens, Greece, that admits c. 19 000 patients
annually. All hospitalised patients were surveyed by obtaining
rectal swab cultures at specified intervals during the study
period. The ICU was not included in the study, as it was
already undergoing active surveillance for VRE and multi-
resistant Gram-negative bacteria. The study protocol was
approved by the hospital’s Ethical Committee. As this measure
was considered to be a relatively minor expansion of the
existing infection control programme for screening patients,
only verbal patient consent was obtained [19].
Protocol for culture of VRE
A rectal swab was collected from every consenting hospita-
lised patient in three consecutive surveys, each of which lasted
5 days (an entire working week). For logistical reasons, the
period between the first two surveys was 25 days, and that
between the second and third surveys was 10 days. The swabs
were transported to the microbiology laboratory for selective
culture of glycopeptide-resistant enterococci. Patients found to
be colonised or infected with VRE were placed under contact
isolation precautions according to CDC guidelines [20].
Patients who were colonised with Enterococcus gallinarum or
Enterococcus casseliflavus were excluded from the study, as
these species demonstrate low-level, intrinsic, chromosomal,
non-transferable vancomycin resistance [21].
Culture, identification and susceptibility testing
Swabs were inoculated on BBL Enterococcosel agar plates
containing vancomycin 6 mg ⁄L (Becton Dickinson Microbiol-
ogy Systems, Cockeysville, MD, USA). All plates were
incubated aerobically at 37C for 48 h. One or more colonies
from each plate that morphologically resembled enterococci
(i.e., with a dark brown halo) were initially identified
according to Gram’s stain, growth in NaCl 6.5% w ⁄v broth
and bile aesculin hydrolysis. Species identification was
performed using the Phoenix Automated Microbiology Sys-
tem (BD Diagnostic Systems, Sparks, MD, USA) according to
the manufacturer’s instructions. Confirmatory identification
of E. faecium was by multiplex PCR based on specific
detection of ddl genes encoding the D-alanine–D-alanine
ligase. MICs of antimicrobial agents were determined using
the broth microdilution method. Isolates with vancomycin
MICs <4 mg ⁄L were classified as vancomycin-susceptible,
isolates with vancomycin MICs of 4–16 mg ⁄L were classified
as intermediate, and isolates with vancomycin MICs
‡32 mg ⁄L were classified as VRE [22]. Susceptibility to
vancomycin and teicoplanin was also assessed using Etests
(AB Biodisk, Dalvagen, Sweden).
Pulsed-field gel electrophoresis (PFGE) typing
Clonal relationships were assessed using PFGE of SmaI-
digested fragments of genomic DNA, performed according
to standard PFGE methods. Macrorestriction fragments were
compared visually for similarities and clonal groups were
determined according to established criteria [23]; i.e., isolates
were considered to be indistinguishable, or closely related, if
there were three or fewer band fragment differences when
compared to the common (modal) type.
Amplification of resistance genes
A multiplex PCR was used with eight different pairs of
primers specific for the identification of E. faecium and E. fae-
calis (16S rRNA) and the vanA, vanB, vanC, vanD, vanG and
vanE glycopeptide resistance genotypes, according to the
protocol described by Depardieu et al. [24]. E. faecalis
ATCC 51299 (vanB) and E. faecalis (vanA) were used as control
strains.
Epidemiological investigation
The study identified patients colonised with VRE (cases). For
each patient colonised with VRE, two patients who failed to
yield VRE isolates in surveillance cultures were randomly
selected as controls from among the entire population
surveyed, with the aid of random number generator software.
Data registered for each patient included demographics,
previous hospitalisation, underlying medical conditions,
immunodeficiency status (e.g., use of immunosuppressive
agents such as glucocorticoids, cyclosporin and anti-cancer
chemotherapy, or infection with human immunodeficiency
virus), hospital ward at time of sampling, presence of an
invasive device (central venous or urinary catheter), exposure
to an antimicrobial agent (both current and previous, i.e.,
within the previous 6 months), and duration of hospital stay
before study entry.
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Statistical analysis
Results were expressed as median and inter-quartile range.
Chi-squared and Fisher’s exact tests were used for categorical
variables. Non-parametric statistical tests (Mann–Whitney’s
U-test or Wilcoxon’s signed-rank test) were used to compare
continuous variables, e.g., age, duration of hospital stay and
duration of antimicrobial use between cases and controls.
Normally distributed variables were compared using analysis
of variance. Spearman’s correlation coefficient was used to
assess the relationship between continuously distributed
variables, e.g., age, length of hospital stay and duration of
antimicrobial use. General logistic regression analysis to
identify predictors of colonisation with VRE was performed
for variables associated with VRE colonisation during univar-
iate analysis (p <0.10), together with selected variables that
have been shown to be significant in previous studies (e.g.,
chronic renal disease, diabetes mellitus). Interactions of spe-
cific terms were also studied. All statistical tests used were
two-sided, with p <0.05 considered to be statistically signifi-
cant. SPSS v.10.0 for Windows (SPSS Inc., Chicago, IL, USA)
was used for data analysis.
RESULTS
Prevalence of VRE colonisation
During the 40-day period of the study, 448
patients from the entire hospital (except the
ICU) were eligible for the survey. Forty (8.9%)
patients were away from the ward at the time
of screening and 38 (8.5%) patients refused
consent. From the remaining 370 (82.5%)
patients, 465 rectal swab specimens were col-
lected, of which 73 (15.7%) from 53 (14.3%)
patients were VRE-positive. The prevalence of
VRE carriage in the three surveys was 19.7%,
14.4% and 9.5%, respectively. All isolates were
identified as E. faecium carrying the vanA gene.
In addition, five clinical isolates (all from
patients in the haematological ward) were iden-
tified as linezolid-resistant E. faecium (vancomy-
cin- and linezolid-resistant enterococci (VLRE)),
with a linezolid MIC of 12 mg ⁄L. These were
the first VLRE isolates identified in this hospital.
None of these five patients was receiving
therapy with linezolid.
PFGE analysis
Eight unique PFGE restriction profiles were
identified. Two clonal types (A and B) were the
most frequent, containing 29 and 25 isolates,
respectively. No association of the most frequent
clonal types with a specific hospital location was
found.
Patients’ characteristics
Clinical features of patients with (n = 53) or
without (n = 106) VRE rectal colonisation are
summarised in Table 1. The two groups did not
differ with respect to age or gender. Patients
colonised with VRE at the time of the initial
culture had a significantly longer current hospital
stay as compared to non-colonised patients.
Univariate analysis showed that VRE-positive
patients were more likely than controls to suffer
from a haematological malignancy or immunode-
ficiency, whereas the presence of a solid tumour,
diabetes mellitus or renal disease was not associ-
ated with VRE colonisation (Table 1).
Antimicrobial use
Exposure to antimicrobial agents before the initial
positive screen for VRE is also shown in Table 1.
VRE-positive patients were more likely to have
been treated with intravenous vancomycin, piper-
acillin–tazobactam, carbapenems, anti-anaerobic
agents, quinolones or any antibiotic (all grouped
together), both during the current period of
hospitalisation and within the previous 6 months.
Preceding exposure to aminopenicillins, amino-
glycosides and cephalosporins was similar for the
two groups. VRE carriers had a longer duration of
any antimicrobial use in the current period of
hospitalisation and before study entry.
Clinical outcome
In terms of clinical outcome, none of the patients
developed a VRE infection during the current
period of hospitalisation. VRE-positive patients
had longer total periods of hospitalisation than
did VRE-negative patients. This difference was
observed in the duration of hospitalisation before
the initial culture as well as afterwards.
Eighteen (11.3%) of 159 patients included in the
study died. VRE-colonised patients were more
likely to die in the hospital, but none of the deaths
was attributable to a VRE infection. The crude
mortality rate for colonised patients was 24.5%
(13 ⁄ 53) as compared to 4.7% (5 ⁄ 106) for patients
who were not colonised with VRE (OR 6.6,
95% CI 2.2–19.6, p <0.001). Univariate analysis
showed that patients who died were older
(p 0.001), more likely to have a malignancy
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(OR 3.6, 95% CI 1.3–10.3, p 0.02) and, more spe-
cifically, a haematological malignancy (OR 3.3,
95% CI 1.1–9.3, p 0.05). In addition, they were
more likely to have an invasive device in place
(OR 7.9, 95% CI 2.4–25.3, p <0.001), a longer
duration of hospitalisation (for a 10-day stay,
OR 3.3, 95% CI 1.2–9.4, p 0.02), and to have had
more prolonged use of any antibiotic (p <0.001).
Multivariate analysis
Logistic regression analysis, after adjustment for
age, gender, duration of hospital stay before the
positive culture result, hospitalisation in specific
wards, presence of immunodeficiency, and hae-
matological malignancy, revealed that the pres-
ence of an invasive device and the duration of
antimicrobial treatment before VRE isolation
(Fig. 1, Table 2) were the most important predic-
tors of VRE colonisation. Regarding exposure to
specific antimicrobial agents, other adjusted mul-
tivariate models have revealed that intravenous
treatment with anti-anaerobic agents, as well as
quinolone use, are associated significantly with
VRE colonisation. In a multivariate model, the
most important predictors of death in the study
group were increasing age and the diagnosis of a
Table 1. Comparison by univariate
analysis of the clinical features,
antimicrobial use and outcomes of
patients with or without vancomy-
cin-resistant enterococci (VRE) rectal
colonisation
Characteristic
VRE-positive
(n = 53) (%)
VRE-negative
(n = 106) (%) p OR (95% CI)
Gender, male (%) 31 ⁄ 53 (58.5) 47 ⁄ 106 (43.9) 0.9
Age, yearsa 67 (52.5–77) 69 (52.8–78) 0.7
Hospitalisation in the preceding 6 months 40 ⁄ 50 (80) 55 ⁄ 104 (52.9) 0.001 3.6 (1.6–7.9)
Hospitalisation in intensive care unit in
the preceding 6 months
5 ⁄ 50 (10) 1 ⁄ 105 (0.95) 0.01 11.6 (1.3–101.7)
Co-morbidities
Haematological malignancy 18 ⁄ 53 (34) 12 ⁄ 106 (11.3) 0.001 4.0 (1.8–9.2)
Solid tumour 10 ⁄ 53 (18.7) 24 ⁄ 106 (22.6) 0.7
Immunodeficiency 27 ⁄ 53 (50.9) 26 ⁄ 106 (24.5) 0.001 3.2 (1.6–7.9)
Diabetes mellitus 14 ⁄ 53 (26.4) 25 ⁄ 105 (23.8) 0.8
Renal disease 7 ⁄ 53 (13.2) 12 ⁄ 105 (11.4) 0.8
Presence of an invasive device 33 ⁄ 49 (67.3) 22 ⁄ 102 (21.6) <0.001 7.5 (3.5–16)
Hospitalisation in the two wards for patients
with haematological malignancy
29 ⁄ 53 (54.7) 32 ⁄ 106 (30.2) 0.003
Hospitalisation days before culturea 18 (6–30) 5 (3–11) <0.001
Hospitalisation for ‡10 days before culture 35 ⁄ 53 (66) 30 ⁄ 106 (28.3) <0.001 4.9 (2.4–10)
Hospitalisation days after culturea 11 (7–22.5) 6 (1–12) 0.001
Length of total hospitalisationa 34 (18–48) 14 (8–26) <0.001
Crude mortality 13 ⁄ 53 (25) 5 ⁄ 106 (4.7) <0.001 6.6 (2.2–19.6)
Antimicrobial use
Previous use of antibiotics (within
preceding 6 months)
35 ⁄ 47 (74.5) 40 ⁄ 90 (44.4) 0.001 3.6 (1.7–7.9)
Current use of any antibiotics (within
the preceding 2 days)
41 ⁄ 53 (77.3) 32 ⁄ 106 (30.2) <0.001 7.9 (3.7–17)
Days of antimicrobial treatment before
culturea
8 (2.5–20) 0 (0–2) <0.001
Vancomycin 13 ⁄ 53 (24.5) 1 ⁄ 106 (0.9) <0.001 34 (4.3–269)
Ampicillin–sulbactam 3 ⁄ 53 (5.7) 7 ⁄ 106 (6.6) 1.0
Piperacillin–tazobactam 18 ⁄ 53 (34) 9 ⁄ 106 (8.5) <0.001 5.6 (2.3–13.5)
Clindamycin 4 ⁄ 53 (7.5) 1 ⁄ 106 (0.9) 0.04
Metronidazole 2 ⁄ 53 (3.8) 8 ⁄ 106 (7.5) 0.5
Anti-anaerobic agentsb 32 ⁄ 53 (60.4) 20 ⁄ 106 (18.9) <0.001 6.6 (3.1–13.7)
Cephalosporins, second generation 3 ⁄ 53 (5.7) 7 ⁄ 106 (6.6) 1.0
Cephalosporins, third and fourth
generations
3 ⁄ 53 (5.7) 3 ⁄ 106 (2.8) 0.4
Quinolones 14 ⁄ 53 (26.4) 6 ⁄ 106 (5.7) 0.001 6 (2.1–16.7)
Aminoglycosides 3 ⁄ 53 (5.7) 2 ⁄ 106 (1.9) 0.3
Carbapenems 11 ⁄ 53 (20.7) 1 ⁄ 106 (0.9) <0.001 27.5 (3.4–220)
aContinuous variables expressed as median (inter-quartile range).
bPiperacillin–tazobactam, ampicillin–sulbactam, amoxycillin–clavulanate, cefoxitin, imipenem–cilastatin,
meropenem, metronidazole or clindamycin.
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Fig. 1. Days of antibiotic treatment (abx) before sampling
for patients positive for colonisation with vancomycin-
resistant enterococci, shown in column 1, and controls,
shown in column 0.
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malignancy, but not VRE colonisation, while the
presence of chronic renal failure approached, but
did not reach, statistical significance (Table 2).
DISCUSSION
This study investigated the clinical characteristics,
antibiotic use, microbiological factors and clinical
outcome of patients colonised with VRE. The
overall prevalence of VRE of 14.4% was some-
what higher than those reported previously by
other investigators in Europe (1.5–8.6%) [11–13]
or specifically in Greece (3.9–7.5%) [25,26]. The
PFGE results, showing that most isolates
belonged to two major clones, with the remainder
belonging to six additional clones, suggest an
endemic situation, combined with an acute
nosocomial outbreak. The two major clones were
not located in specific wards, but were dissemi-
nated throughout the hospital. In multivariate
analysis, two major variables were found to be
associated with VRE colonisation, i.e., the pres-
ence of an invasive device and the duration of any
antimicrobial treatment before VRE isolation.
Intravenous treatment with anti-anaerobic agents,
and the use of quinolones, were also found to be
related positively to VRE colonisation.
The association between VRE colonisation or
infection and certain underlying medical condi-
tions, e.g., diabetes mellitus, chronic renal failure,
malignancies and transplantation, is well-known
[4,9,16,27,28]. In the present study, haematology
patients were identified as a group at increased
risk for VRE colonisation in univariate analysis.
However, hospitalisation in wards where the vast
majority of patients suffer from a haematological
disease was also associated with VRE colonisa-
tion. This association is further confounded by the
fact that most patients in haematology wards are
heavily exposed to broad-spectrum antibiotics,
resulting in higher colonisation pressure and
enhanced spread of VRE [28]. Matar et al. [9]
have reported that a significant proportion (29%)
of VRE-colonised patients with haematological
malignancy develop a subsequent VRE bactera-
emia, or another infection (32%), mostly while
neutropenic (71%).
The presence of an invasive device has been
identified previously as a strong clinical risk-
factor for VRE invasive infections [28]. It is
unclear whether catheters serve as the actual
conduit through which VRE infection is acquired,
or whether they are just markers of debilitation,
prolonged hospitalisation and severe co-morbid-
ities.
The possibility that preceding antimicrobial
treatment is a risk-factor for nosocomial VRE
has been explored in numerous studies of both
colonised and infected patients, with conflicting
results [15]. The most important agents reported
are vancomycin [4,10,28–30], cephalosporins
[10,16,18,29,31,32] and antimicrobial agents with
an anti-anaerobic spectrum [4,16,32–34]. The exact
role of vancomycin may need further elucidation.
It has been reported that ongoing vancomycin use
maintains an intestinal environment favourable to
VRE growth, thus increasing the likelihood of
VRE entry into the bloodstream [30]. Preceding
treatment with vancomycin was more common in
VRE-positive patients in the present study, but
this association did not reach statistical signifi-
cance in multivariate models. A meta-analysis by
Carmeli et al. [35] revealed that the reported
strong association between vancomycin treatment
and hospital-acquired VRE is the result of refer-
ence group selection and of publication bias
confounded by a longer duration of hospitalisa-
tion. The present study, which accounted for
these factors, revealed only a small and non-
significant association, which is in concordance
with other studies [4,15,31,33]. Glycopeptide use
may promote the possibility of a VRE carrier
becoming a transmitter, rather than increasing the
risk of a non-carrier becoming colonised [15,36].
The present study revealed a significant asso-
ciation between exposure to agents with anti-
anaerobic activity and VRE colonisation. These
Table 2. Multivariate analysis of risk-factors for colonisa-
tion with vancomycin-resistant enterococci (VRE) and
death
Variable OR (95% CI) p
Risk of VRE colonisation
Any invasive device 4.8 (1.7–13.5) 0.003
Duration of any antimicrobial
treatment before VRE isolationa
1.2 (1.1–1.3) <0.001
Specific antimicrobial exposureb
Anti-anaerobic agents 4.8 (1.9–12) 0.001
Quinolone 4.1 (1.1–15.3) 0.03
Risk of in-hospital death
Increasing agec 1.08 (1.02–1.15) 0.009
Malignancy 8.2 (1.2–53.8) 0.03
VRE colonisation 3.1 (0.6–15.1) 0.2
Chronic renal failure 6.4 (0.8–53.5) 0.09
aOR expressed per additional day of treatment.
bIn models adjusting for age, gender, immunodeficiency, duration of hospital stay
before the positive culture result, and presence of a haematological malignancy or
an invasive device.
cOR expressed per additional year.
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agents may increase VRE colonisation in the
lower gastrointestinal tract [4] through suppres-
sion of gastrointestinal anaerobic flora [16].
A higher risk of bacteraemia has been observed
in such patients [37], and limiting the use of anti-
anaerobic agents may therefore help to decrease
the spread of VRE [21].
The relationship between exposure to fluoro-
quinolones and VRE colonisation or infection is
unclear. A significant association was revealed
between exposure to fluoroquinolones and VRE
colonisation in some, but not all, of the multi-
variate models examined (data not shown). A
meta-analysis of ten studies revealed a possible
role of quinolones in the nosocomial epidemiol-
ogy of VRE [38]. Other studies have demon-
strated the importance of the duration of
exposure to quinolones [15] and ⁄ or their use as
a prophylaxis regimen [39].
The failure of the present study to detect the
well-known association between exposure to
third-generation cephalosporins and VRE coloni-
sation [10,16,18,29,31,33] may be related to the
limited use of these drugs in this institution.
Nevertheless, the data confirm the importance of
the length of antimicrobial exposure, rather than
the use of specific antimicrobial agents.
Other factors may also be important. In uni-
variate analyses, hospitalisation in a medical
ward or admission to the ICU during the preced-
ing 6 months was associated with VRE colonisa-
tion. These results either reflect an increased
severity of illness in the population studied or
may represent previous VRE acquisition in high-
risk environments [27,40].
Colonisation with VRE may lead to invasive
infections, but no such events were observed
during this study, despite the fact that all patients
were followed until discharge. It has been shown
that VRE colonisation is universally present in
patients developing bacteraemia [4], and a study
of immunodeficient patients revealed a high
negative predictive value (99.9%) and a positive
predictive value of 29.3% for VRE colonisation
with the development of bacteraemia [9]. VRE
bacteraemia may emerge in the setting of pro-
longed gastrointestinal colonisation as an isolated
breakthrough event under heavy antimicrobial
treatment.
Invasive VRE infections have been associated
with high morbidity and mortality rates [1–4].
Previous studies have attributed the higher crude
mortality rate observed in patients infected with
VRE to the underlying severity of illness [28,39].
In the present study, prolonged hospitalisation
and high crude mortality rates were related to
VRE isolation in univariate analyses. However, as
in other studies, VRE colonisation was not an
independent risk-factor for all-cause mortality
[10,33]. As expected, the main predictors of death
were underlying malignancy and increasing age.
The present study was limited by its cross-
sectional design and the specific setting studied.
For example, the risk of colonisation could not be
assessed in patients who were initially free of
VRE [19], and the results may have been affected
by the individual practices of physicians in the
hospital. The observed results apply to the indi-
vidual risk of VRE colonisation and do not
consider the role of transmission of VRE from
other patients, most likely via the hands of
healthcare workers or contamination of environ-
mental surfaces. It has been reported that poor
infection control practices, admission of patients
who are already colonised, antibiotic use and
prolonged hospitalisation all contribute to the
spread of VRE in hospitals [37].
Haematological patients with invasive devices,
who are treated with antibiotics for a prolonged
period in the same ward, may have served as a
reservoir for VRE spread. The importance of
proximity in time and space to culture-positive
patients for transmission of VRE has been shown
previously [34], but was not analysed in the
present study. Byers et al. [34] revealed that
proximity to non-isolated, colonised patients
was an important risk-factor for acquisition of
VRE, and also suggested that antibiotic exposure
is an important, but insufficient, precondition for
developing a positive VRE culture among pa-
tients who have not previously been exposed to
VRE. Although a careful attempt was made to
adjust for most confounders, residual confound-
ing could not be taken into account.
Enterococci have now emerged as significant
urinary tract, surgical wound and bloodstream
pathogens. The discovery of a globally dispersed
clonal lineage of the virulent hospital-adapted
clone of E. faecium (CC-17) has provided an
explanation for the rapid spread of resistant
strains within the hospital environment. The
acquisition of ampicillin resistance and the puta-
tive esp pathogenicity island by E. faecium has
improved the relative fitness of this species in
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hospital environments, thereby facilitating
transmission and leading to nosocomial outbreaks
[41]. However, 10- to 20-fold more patients are
colonised than are infected [36], and the most
interesting studies are those that investigate the
epidemiology of colonisation with VRE [42], with
the expectation that VRE colonisation will even-
tually lead to infections [32]. In one study, 14% of
colonised patients eventually yielded a positive
clinical culture a median of 15 days after a
positive surveillance culture [43]. Identification
of the patient groups at risk of colonisation, and
the implementation of aggressive screening and
infection control measures, are necessary [43,44]
and effective [27,45]. Infection control measures
designed to prevent nosocomial spread of VRE
remain important [20,45,46], although incomplete
compliance with these measures is a problem
[4,28,40].
The present study suggested that patients with
an invasive device and heavy antimicrobial expo-
sure constituted the group at highest risk of VRE
colonisation. Although not identified in this
study, such colonisation may eventually account
for increased rates of clinical infection [4,9]. Thus
an active surveillance programme was instituted
for early detection of VRE-colonised patients,
specifically targeting the groups at highest risk
in the hospital. An effort was also made to control
antibiotic use more effectively and to strictly
implement a hand hygiene policy. The drop in
prevalence in the three consecutive surveys may
indicate a fluctuation with time, although specific
control measures were implemented after the first
screening period. These efforts might have biased
some of the associations observed, although a
hospital with continuous movement of patients
would expect some of the factors inherent in VRE
colonisation to remain unchanged (i.e., presence
of a malignancy or an invasive device). Long-term
evaluation of these measures is ongoing and
should help to control future outbreaks of clinical
infection with this multiresistant pathogen. Stud-
ies with similar design may be used to devise
targeted, and perhaps more effective, control
strategies for VRE.
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